Catabasis Pharmaceuticls Inc. (CATB) Stock Rating Reaffirmed by Wedbush

Catabasis Pharmaceuticls Inc. (NASDAQ:CATB)‘s stock had its “outperform” rating reissued by Wedbush in a note issued to investors on Thursday. They presently have a $17.00 target price on the stock. Wedbush’s price objective points to a potential upside of 279.46% from the company’s previous close.

Several other analysts have also issued reports on CATB. Cowen and Company restated a “buy” rating on shares of Catabasis Pharmaceuticls in a research note on Wednesday, June 8th. Zacks Investment Research upgraded Catabasis Pharmaceuticls from a “hold” rating to a “buy” rating and set a $4.25 price objective on the stock in a research note on Tuesday, July 5th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $19.05.

Catabasis Pharmaceuticls (NASDAQ:CATB) traded up 59.82% during mid-day trading on Thursday, reaching $7.16. The company had a trading volume of 8,821,163 shares. Catabasis Pharmaceuticls has a 12-month low of $3.31 and a 12-month high of $10.83. The stock has a 50 day moving average price of $4.66 and a 200-day moving average price of $4.77. The stock’s market capitalization is $110.13 million.

Catabasis Pharmaceuticls (NASDAQ:CATB) last issued its earnings results on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.04. Equities analysts anticipate that Catabasis Pharmaceuticls will post ($2.47) EPS for the current fiscal year.

An institutional investor recently bought a new position in Catabasis Pharmaceuticls stock. Bridgeway Capital Management Inc. bought a new position in Catabasis Pharmaceuticls Inc. (NASDAQ:CATB) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 27,700 shares of the company’s stock, valued at approximately $102,000. Bridgeway Capital Management Inc. owned approximately 0.18% of Catabasis Pharmaceuticls as of its most recent filing with the SEC. 66.58% of the stock is currently owned by institutional investors.

Catabasis Pharmaceuticls Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Ratings for Catabasis Pharmaceuticls Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticls Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.